MedTrace Logo

Iadademstat With Hypomethylating Agent in Patients With Myelodysplastic Syndrome

NCT06502145 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2026-04-03

No results posted yet for this study

Summary

This is a phase I study with a primary objective of determining the recommended phase II dose of iadademstat with azacitidine in adult subjects with myelodysplastic syndrome (MDS).

Conditions

Interventions

DRUG

Azacitidine Level -1

Intravenous (IV) or subcutaneous (SC) 75 mg / m\^2 days 1-7 X 28 days.

DRUG

Azacitidine Level 0

Intravenous (IV) or subcutaneous (SC) 75 mg / m\^2 days 1-7 X 28 days.

DRUG

Azacitidine Level 1

Intravenous (IV) or subcutaneous (SC) 75 mg / m\^2 days 1-7 X 28 days.

DRUG

Iadademstat Level -1

75 µg by mouth (PO) 5 days on, 2 days off for 2 weeks every 28 days.

DRUG

Iadademstat Level 0

75 µg PO 5 days on, 2 days off for 3 weeks every 28 days.

DRUG

Iadademstat Level 1

100 µg PO 5 days on, 2 days off for 3 weeks every 28 days.

Sponsors & Collaborators

  • Medical College of Wisconsin

    lead OTHER

Principal Investigators

  • Guru Subramanian Guru Murthy, MD, MS · Medical College of Wisconsin

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-10
Primary Completion
2026-12-31
Completion
2027-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06502145 on ClinicalTrials.gov